• Je něco špatně v tomto záznamu ?

Identification of a four-gene methylation biomarker panel in high-grade serous ovarian carcinoma

I. Baranova, H. Kovarikova, J. Laco, I. Sedlakova, F. Vrbacky, D. Kovarik, P. Hejna, V. Palicka, M. Chmelarova

. 2020 ; 58 (8) : 1332-1340. [pub] 20200728

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026640

Background The lack of effective biomarkers for the screening and early detection of ovarian cancer (OC) is one of the most pressing problems in oncogynecology. Because epigenetic alterations occur early in the cancer development, they provide great potential to serve as such biomarkers. In our study, we investigated a potential of a four-gene methylation panel (including CDH13, HNF1B, PCDH17 and GATA4 genes) for the early detection of high-grade serous ovarian carcinoma (HGSOC). Methods For methylation detection we used methylation sensitive high-resolution melting analysis and real-time methylation specific analysis. We also investigated the relation between gene hypermethylation and gene relative expression using the 2-ΔΔCt method. Results The sensitivity of the examined panel reached 88.5%. We were able to detect methylation in 85.7% (12/14) of early stage tumors and in 89.4% (42/47) of late stage tumors. The total efficiency of the panel was 94.4% and negative predictive value reached 90.0%. The specificity and positive predictive value achieved 100% rates. Our results showed lower gene expression in the tumor samples in comparison to control samples. The more pronounced downregulation was measured in the group of samples with detected methylation. Conclusions In our study we designed the four-gene panel for HGSOC detection in ovarian tissue with 100% specificity and sensitivity of 88.5%. The next challenge is translation of the findings to the less invasive source for biomarker examination, such as plasma. Our results indicate that combination of examined genes deserve consideration for further testing in clinical molecular diagnosis of HGSOC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026640
003      
CZ-PrNML
005      
20211026132732.0
007      
ta
008      
211013s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1515/cclm-2019-1319 $2 doi
035    __
$a (PubMed)32145055
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Baranova, Ivana $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
245    10
$a Identification of a four-gene methylation biomarker panel in high-grade serous ovarian carcinoma / $c I. Baranova, H. Kovarikova, J. Laco, I. Sedlakova, F. Vrbacky, D. Kovarik, P. Hejna, V. Palicka, M. Chmelarova
520    9_
$a Background The lack of effective biomarkers for the screening and early detection of ovarian cancer (OC) is one of the most pressing problems in oncogynecology. Because epigenetic alterations occur early in the cancer development, they provide great potential to serve as such biomarkers. In our study, we investigated a potential of a four-gene methylation panel (including CDH13, HNF1B, PCDH17 and GATA4 genes) for the early detection of high-grade serous ovarian carcinoma (HGSOC). Methods For methylation detection we used methylation sensitive high-resolution melting analysis and real-time methylation specific analysis. We also investigated the relation between gene hypermethylation and gene relative expression using the 2-ΔΔCt method. Results The sensitivity of the examined panel reached 88.5%. We were able to detect methylation in 85.7% (12/14) of early stage tumors and in 89.4% (42/47) of late stage tumors. The total efficiency of the panel was 94.4% and negative predictive value reached 90.0%. The specificity and positive predictive value achieved 100% rates. Our results showed lower gene expression in the tumor samples in comparison to control samples. The more pronounced downregulation was measured in the group of samples with detected methylation. Conclusions In our study we designed the four-gene panel for HGSOC detection in ovarian tissue with 100% specificity and sensitivity of 88.5%. The next challenge is translation of the findings to the less invasive source for biomarker examination, such as plasma. Our results indicate that combination of examined genes deserve consideration for further testing in clinical molecular diagnosis of HGSOC.
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    12
$a metylace DNA $7 D019175
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory vaječníků $x krev $x diagnóza $x genetika $7 D010051
650    _2
$a senzitivita a specificita $7 D012680
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kovarikova, Helena $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Sedlakova, Iva $u Department of Obstetrics and Gynecology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Vrbacky, Filip $u The 4th Department of Internal Medicine - Hematology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Kovarik, Dalibor $u Department of Forensic Medicine, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Hejna, Petr $u Department of Forensic Medicine, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Palicka, Vladimir $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Chmelarova, Marcela $u Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
773    0_
$w MED00010886 $t Clinical chemistry and laboratory medicine $x 1437-4331 $g Roč. 58, č. 8 (2020), s. 1332-1340
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32145055 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132738 $b ABA008
999    __
$a ok $b bmc $g 1715392 $s 1147147
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 58 $c 8 $d 1332-1340 $e 20200728 $i 1437-4331 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...